A recent study has found a newly developed compound that starves cancer cells by attacking their ‘power plants’ - the so-called mitochondria. The new compound prevents the genetic information within mitochondria from being read. Researchers from the Max Planck Institute for Biology of Ageing in Cologne, the Karolinska Institute in Stockholm, and the University of Gothenburg report in their study that this compound could be used as a potential anti-tumour drug in the future; not only in mice but also in human patients. Mitochondria provide our cells with energy and cellular building blocks necessary for normal tissue and organ function. For a long time, the growth of cancer cells was assumed to be independent of mitochondrial function. However, this long-standing dogma has been challenged in recent years. Especially cancer stem cells are highly dependent on mitochondrial metabolism. Due to the central role of mitochondria for normal tissue function, and because drugs that target mitochondrial functions are usually very toxic, it has so far proven difficult to target mitochondria for cancer treatment.

Immunology is a branch of biomedical science which deals with an organism’s response towards an invading environmental factor. This process involves a complex interplay of invading particle and defence system of the host organism along with successive cascading molecular mechanism to eliminate the invading agent.

This peer reviewed journal includes clinical and cellular Immunological aspects such as Systemic Lupus Erythmatosus, Cancer Immunology, Tumor Biology, Macrophage Polarization, Transplantation Immunology, Innate Immunology, Adaptive Immunity, Cellular & Molecular Immunology, Vaccine Development, Signal Transduction, Innate Immunity, Cancer Immunotherapy, Inflammatory Disorders, Medical Immunology, Diagnostic Immunology, Clinical Immunology, HIV Immunology, Allergy & Immunology, Immunomodulation, Multiple Sclerosis, Neuroinflammatory Diseases, Clinical & Vaccine Immunology, Clinical Experimental Immunology, T-cell Immunology etc.

This Science Journal publishes research articles, reviews, case studies, commentaries, short communications, and letters to the editor on various aspects of Cellular and Clinical Immunology making them freely available worldwide.To attain high impact factor, quality articles are expected from all over the world for this open access and peer reviewed front running journal.

Journal of Clinical & Cellular Immunology is using Editorial Manager System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking systems used by most of the best open access journals. Review processing is performed by the editorial board members of Journal of Clinical & Cellular Immunology or outside experts; at least two independent reviewers approval followed by editor's approval is required for acceptance of any citable manuscript. Annual  reviews of Immunology Journal is also shared with authors.

Authors are requested to submit manuscripts at https://www.longdom.org/submissions/clinical-cellular-immunology.html 

Media Contact:
Mercy Eleanor
Managing Editor
Journal of Clinical and Cellular Immunology
ISSN: 2155-9899 | NLM ID: 101563152
What’s App: +1-504-608-2390